Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PAK4 Antibodies:
anti-Mouse (Murine) PAK4 Antibodies:
anti-Rat (Rattus) PAK4 Antibodies:
Go to our pre-filtered search.
Bat Polyclonal PAK4 Primary Antibody for WB - ABIN610860
Jones, Jakubowicz, Pitossi, Maurer, Hemmings: Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. in Proceedings of the National Academy of Sciences of the United States of America 1991
Show all 2 Pubmed References
Human Polyclonal PAK4 Primary Antibody for IHC, ELISA - ABIN1002957
Jaffer, Chernoff: p21-activated kinases: three more join the Pak. in The international journal of biochemistry & cell biology 2002
Show all 3 Pubmed References
Human Polyclonal PAK4 Primary Antibody for ELISA, IF - ABIN4343475
Liu, Yang, Liu, Liu, Zhang, Xu, Zhu, Xu: p21-Activated kinase 4 predicts early recurrence and poor survival in patients with nonmetastatic clear cell renal cell carcinoma. in Urologic oncology 2015
Human Polyclonal PAK4 Primary Antibody for WB - ABIN4343476
Cianciola, Chung, Manor, Carlin: Adenovirus Modulates Toll-Like Receptor 4 Signaling by Reprogramming ORP1L-VAP Protein Contacts for Cholesterol Transport from Endosomes to the Endoplasmic Reticulum. in Journal of virology 2017
this series of compounds has the potential for further development as PAK4 inhibitors for anticancer activity
X-ray crystallography reveals that in addition to the canonical PAK4 CDC42 (show CDC42 Antibodies)/RAC (show AKT1 Antibodies) interactive binding (CRIB (show SCRIB Antibodies)) domain binding to CDC42 (show CDC42 Antibodies) there are unexpected contacts involving the PAK4 kinase C-lobe, CDC42 (show CDC42 Antibodies), and the PAK4 polybasic region.
High PAK4 expression is associated with glioma.
These results indicate that miR485 acts as a tumour suppressor in Glioblastoma (GBM) by, at least partially, directly targeting PAK4 and regulating the AKT (show AKT1 Antibodies) and ERK (show EPHB2 Antibodies) signalling pathways. Thus, miR485 may be a potential target for the treatment of patients with GBM.
Study reports the overexpression of PAK4 in neuroblastoma (show ARHGEF16 Antibodies) cells and, that PF-3758309, a potent PAK4 inhibitor, inhibits cell proliferation and survival in neuroblastoma (show ARHGEF16 Antibodies) cells via inhibition of the MEK (show MAP2K1 Antibodies)/ERK (show EPHB2 Antibodies) pathway. These results suggest a role of PAK4 in neuroblastoma (show ARHGEF16 Antibodies) development.
Methylation at cg14010619 may modify PAK4 activity, which has been implicated in cisplatin resistance in malignant cell lines
PAK4 downregulated the level of p21 (show CDKN1A Antibodies) and enhanced the activity of Akt (show AKT1 Antibodies) as well. And we conclude that PAK4 acts as a regulator of cell cycle (show C13orf15 Antibodies) progression of vascular smooth muscle cells by mediating Akt (show AKT1 Antibodies) signaling and controlling p21 (show CDKN1A Antibodies) levels, which further modulate intimal hyperplasia and vascular smooth muscle cells proliferation
Findings revealed a novel function of PAK4 in thyroid stimulating hormone-induced papillary thyroid cancer progression.
The present study demonstrates that miR (show MLXIP Antibodies)-145 plays an important role in inhibiting cell migration by directly targeting PAK4, and identifies miR (show MLXIP Antibodies)-145-PAK4-LIMK1 (show LIMK1 Antibodies)-cofilin (show CFL1 Antibodies) as a novel regulatory pathway that contributed to colorectal cancer metastasis.
These findings revealed a novel glucose metabolism-related mechanism of PAK4 in promoting colon cancer cell growth, suggesting that PAK4 and/or G6PD (show G6PD Antibodies) blockage might be a potential therapeutic strategy for colon cancer.
PAK4 crystal structures can be classified into specific conformational groups, and that these groups are associated with previously unobserved hinging motions and an unusual conformation for the kinase hydrophobic core. Our findings therefore indicate that there may be a diversity of kinase hinging motions, and that these may indicate different mechanisms of regulation.
PAK4 microparticles may have a role in the ventilation-induced lung injury process
These data demonstrate the relevance of PAK4 in osteoclast differentiation and the potential of PAK4 inhibitors for treating osteoclast-related disorders.
PAK4 promotes alpha-MSH/UVB-induced melanogenesis via the CREB (show CREB1 Antibodies) and Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling pathways and suggest that PAK4 may be a potential therapeutic target in pigmentation disorders.
PAK4 phosphorylates Par6B (show PARD6B Antibodies) at Ser143 blocking its interaction with Cdc42 (show CDC42 Antibodies).
Defined here is the overlap in phosphopeptides regulated by K-Ras (show HRAS Antibodies), Cdc42 (show CDC42 Antibodies), and PAK4; perturbation of these signaling components affects phosphoproteins associated with microtubule depolymerization, cytoskeletal organization, and the cell cycle.
These results indicate that PAK4 functions, including control of actin dynamics, are necessary for normal development of the heart
p21-activated kinase 4 regulates regulatory myosin light chain phosphorylation and myosin contractility during FcgammaR-mediated phagocytosis.
the transient increase in PAK4 levels at early G1 reduces p21 (show D4S234E Antibodies) levels, thereby abrogating the activity of CDK4 (show CDK4 Antibodies)/CDK6 (show CDK6 Antibodies) kinases, and allowing cells to proceed with the cell cycle in a precisely coordinated way
Conditional Pak4 knockout mice were born normally, but displayed growth retardation and died prematurely. The brains showed a dramatic decrease in proliferation of cortical and striatal neuronal progenitor cells.
pak4 is dispensable in zebrafish.
Zebrafish pak4 is required for primitive myeloid cell development.
PAK proteins, a family of serine/threonine p21-activating kinases, include PAK1, PAK2, PAK3 and PAK4. PAK proteins are critical effectors that link Rho GTPases to cytoskeleton reorganization and nuclear signaling. They serve as targets for the small GTP binding proteins Cdc42 and Rac and have been implicated in a wide range of biological activities. PAK4 interacts specifically with the GTP-bound form of Cdc42Hs and weakly activates the JNK family of MAP kinases. PAK4 is a mediator of filopodia formation and may play a role in the reorganization of the actin cytoskeleton. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.
, p21(CDKN1A)-activated kinase 4
, p21-activated kinase 4
, protein kinase related to S. cerevisiae STE20, effector for Cdc42Hs
, serine/threonine-protein kinase PAK 4
, p21 (CDKN1A)-activated kinase 4
, p21 protein (Cdc42/Rac)-activated kinase 4